Munisakhon Majidovna Makhkamova

Dr. Munisakhon Majidovna Makhkamova

Tashkent State Medical University, Tashkent, Toshkent, Uzbekistan
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025
Verified
Journal Article
Open access
PDF file
NNNargiza Nurillaeva
Nargiza Nurillaeva
NSNigora Srojidinova
Nigora Srojidinova
Munisakhon Majidovna MakhkamovaMunisakhon Majidovna Makhkamova
Munisakhon Majidovna Makhkamova
LKLola Khafizova
Lola Khafizova
This review synthesizes current evidence on early biomarkers of endothelial dysfunction (ED) in cardiovascular disease (CVD), emphasizing their role in diagnosis, prognosis, and management. ED, characterized by reduced nitric oxide bioavailability and increased inflammation, serves as a reversible precursor to atherosclerosis, thrombosis, and events like myocardial infarction. Established biomarkers, including adhesion molecules, cytokines, and inflammatory markers, reflect endothelial activation and predict CVD risk, with recent studies confirming their utility in hypertension. Emerging focus on L-arginine derivatives, particularly asymmetric dimethylarginine (ADMA), highlights its specificity as an endogenous nitric oxide synthase inhibitor, associated with vascular impairment in hypertension, diabetes, and CVD. Clinical trials, such as the AtheroGene and Framingham Offspring studies, demonstrate ADMA’s prognostic value for major adverse events. Future directions advocate integrating ADMA into multi-biomarker panels with AI and omics for personalized medicine, addressing gaps in standardization and early detection. Non-invasive techniques like flow-mediated dilation and ultrasound-derived markers complement biomarkers for subclinical CVD assessment. Overall, biomarker-driven strategies promise enhanced CVD prevention and tailored therapies.

30 December 2024
Verified
Journal Article
Open access
PDF file
Munisakhon Majidovna MakhkamovaMunisakhon Majidovna Makhkamova
Munisakhon Majidovna Makhkamova
NNNargiza Nurillaeva
Nargiza Nurillaeva
Цель: Изучить взаимосвязь между метаболически ассоциированной стеатозной болезнью печени (МАСБП) и ишемической болезнью сердца (ИБС), выявить клинические аспекты их коморбидности. Материалы и методы: В исследование включены данные 110 пациентов с ИБС. Диагноз МАСБП устанавливался с использованием ультразвукового исследования печени и анализа метаболических параметров. Проводился корреляционный и регрессионный анализ связи между метаболическими нарушениями и тяжестью ИБС. Результаты: МАСБП выявлена у 77,3% пациентов с ИБС. Тяжесть стеатоза печени коррелировала с уровнем С-реактивного белка, индексом HOMA-IR и частотой острых коронарных событий. У пациентов с выраженной степенью стеатоза чаще диагностировались инфаркт миокарда и дислипидемия. Заключение: МАСБП является значимым фактором риска и утяжеляет течение ИБС. Ранняя диагностика и коррекция метаболических нарушений необходимы для улучшения прогноза пациентов с данной коморбидностью.

29 June 2026
Verified
Journal Article
Open access
PDF file
Munisakhon Majidovna MakhkamovaMunisakhon Majidovna Makhkamova
Munisakhon Majidovna Makhkamova
NNNargiza Nurillaeva
Nargiza Nurillaeva
Endothelial dysfunction is a central pathophysiological process underlying the initiation and progression of cardiovascular disease and is characterized by impaired nitric oxide (NO) bioavailability, increased oxidative stress, inflammation, vasoconstriction, and prothrombotic vascular signaling. Among the endogenous regulators of the NO pathway, asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, has emerged as an important molecular link between metabolic stress and vascular dysfunction. However, circulating ADMA represents only one component of a broader regulatory network involving protein arginine methyltransferases (PRMTs), dimethylarginine dimethylaminohydrolases (DDAHs), and alternative methylarginine-metabolizing pathways. This review examines the molecular architecture of the PRMT–ADMA–DDAH–eNOS/NO axis and its contribution to atherosclerosis, coronary artery disease, hypertension, heart failure, cardiometabolic disorders, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease. Finally, we discuss the therapeutic potential and limitations of targeting PRMT activity, ADMA metabolism, DDAH1, AGXT2, and NO bioavailability. Understanding this regulatory network may provide a mechanistic framework for identifying endothelial phenotypes of residual cardiovascular risk and developing more individualized strategies for cardiovascular prevention and treatment.

30 December 2024
Verified
Journal Article
Open access
Munisakhon Majidovna MakhkamovaMunisakhon Majidovna Makhkamova
Munisakhon Majidovna Makhkamova
NNNargiza Nurillaeva
Nargiza Nurillaeva
Background. To investigate the association between metabolically associated steatotic liver disease (MASLD) and ischemic heart disease (IHD), focusing on the clinical aspects of their comorbidity. Materials and methods. Data from 110 patients with IHD were analyzed. MASLD was diagnosed using liver ultrasound and metabolic parameters. Correlation and regression analyses were conducted to evaluate the relationship between metabolic disturbances and IHD severity. Results. MASLD was identified in 77.3% of patients with IHD. The severity of liver steatosis correlated with C-reactive protein levels, HOMA-IR index, and the frequency of acute coronary events. Patients with severe steatosis were more likely to experience myocardial infarction and dyslipidemia. Conclusion. MASLD is a significant risk factor that exacerbates the course of IHD. Early diagnosis and correction of metabolic disorders are essential for improving the prognosis of patients with this comorbidity.

27 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
Munisakhon Majidovna MakhkamovaMunisakhon Majidovna Makhkamova
Munisakhon Majidovna Makhkamova
NNNargiza Nurillaeva
Nargiza Nurillaeva
Dinara NurkinaDinara Nurkina
Dinara Nurkina
FYFarrux Shuxratovich Yuldashev
Farrux Shuxratovich Yuldashev
DUDoston Ubaydullayev
Doston Ubaydullayev
Background: Coronary artery disease (CAD) frequently coexists with cardiometabolic and hepatic dysfunction, yet accessible biomarkers capturing this convergence remain limited. Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, has been proposed as an integrative marker of endothelial and metabolic impairment. This study aimed to evaluate the diagnostic value of ADMA as a unified biomarker of endothelial dysfunction (ED), cardiometabolic burden, and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with stable CAD. Methods: In this cross-sectional study, 298 patients with stable CAD (functional class I–II) were enrolled at two centers in Tashkent, Uzbekistan. Serum ADMA was measured by ELISA; endothelial function was assessed by flow-mediated dilation (FMD). Associations between ADMA, metabolic indices, MASLD, and CAD severity were analyzed. Results: MASLD was present in 48.3% of CAD patients and metabolic syndrome (MetS) in 62.4%. Patients with MASLD had more severe angina, reduced exercise tolerance, and greater ischemic burden than those without. ADMA correlated positively with BMI, waist circumference, TyG index, and TG/HDL-C ratio (all p < 0.001), with the TyG index showing the strongest predictive value for elevated ADMA (AUC 0.76). A dose–response relationship linked rising ADMA to worsening FMD; concentrations >160 ng/mL conferred markedly increased odds of overt ED (OR 114.8, 95% CI 6.8–1935.0) and were disproportionately prevalent in patients with MASLD (93.1% vs. 61.0%, p < 0.001). Conclusions: ADMA is markedly elevated in stable CAD and closely tracks endothelial, metabolic, and hepatic dysfunction. These cross-sectional associations position ADMA as a promising, hypothesis-generating integrative biomarker; prospective longitudinal studies are needed before its use for risk stratification in primary and cardiovascular care can be recommended.